This EMCDDA Trendspotter study on Internet drug markets in Europe was undertaken during September and October 2014. It commenced with a phase of data collection
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter referred to as the ‘Decision’) stipulates that ‘Where Europol and the EMCDDA, or the Council, acting by a
At the end of September 2013, the EMCDDA and Europol examined the available information on a new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2- methoxybenzyl)phenethylamine, commonly known by the abbreviation ‘25I-NBOMe’, through
The EMCDDA–Europol Joint Report on new psychoactive substance AH-7921 (3,4-dichloro-N-[[1 (dimethylamino)cyclohexyl]methyl]benzamide), submitted in December 2013 to the Council of the EU, the European Commission and
The EMCDDA–Europol Joint Report on new psychoactive substance (3,4-methylenedioxypyrovalerone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA.